RELAY THERAPEUTICS INC (RLAY)
Health Care · Clinical-stage biopharmaceutical drug discovery and development · NASDAQ
Early-stage biotech leveraging structure-based drug design to develop small-molecule therapeutics addressing oncology and other diseases.
What RELAY THERAPEUTICS INC does
Relay Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drug candidates through structure-based drug design. The company has not yet completed any large-scale pivotal clinical trials, has no approved products, and generates no revenue from product sales. Relay is advancing multiple product candidates through clinical development while building proprietary drug discovery and development capabilities.
Themes: ["oncology","small-molecule drugs","clinical-stage development","drug discovery"]
Fundamentals
- Price$20.75 as of 2026-07-09 close
- Market cap$4.5B as of 2026-07-10
- 1-year return+446.8% as of 2026-07-09 close
- Net margin-1859.7% as of 2026-07-10
- ROE-43.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+39.0% as of 2026-07-10
- Revenue CAGR (3y)+123.2% SEC XBRL
- Beta1.66 as of 2026-07-10
Key risks (from latest filing)
["Never successfully completed large-scale pivotal clinical trials and ability to do so is uncertain","Clinical trial delays, patient enrollment challenges, and potential regulatory holds could delay or prevent commercialization","No approved products and no product revenue; dependent on raising substantial additional funding to continue operations"]
Competitors & peers
- Genentech
- Roche
- Bristol Myers Squibb (BMY)
- Merck & Co. (MRK)
- Eli Lilly (LLY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.